• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Correspondence The future of stroke therapy must not be mired by past arguments
Stroke is the leading cause of disability and the fifth leading cause of death in the UK, costing the UK economy more than £7 billion per year.1 At present, the only therapeutic approved by the UK National Institute for Health and Care Excellence (NICE) for the treatment of ischaemic stroke is thrombolysis using recombinant tissue-type plasminogen activator (rtPA). However, rtPA is only effective in patients who present within 4·5 h of stroke onset, with a number needed to treat for benefit of 3·6 before 90 min, rising to 5·9 between 3 h and 4·5 h.
Source: LANCET - August 14, 2015 Category: Journals (General) Authors: Alastair M Buchan, Hasneen G Karbalai, Brad A Sutherland Tags: Correspondence Source Type: research

Editorial Statins for millions more?
Last week, the National Institute for Health and Care Excellence (NICE) in the UK unveiled draft guidance on cardiovascular risk assessment and, in particular, on lipid modification for the primary and secondary prevention of cardiovascular disease. In an update to the existing guideline, the new proposal is that the threshold be halved for prescribing statins to prevent cardiovascular disease, which includes coronary heart disease and stroke.
Source: LANCET - February 21, 2014 Category: Journals (General) Authors: The Lancet Tags: Editorial Source Type: research